Armata Pharmaceuticals (NYSEMKT:ARMP) is up 43% premarket after receiving a $15M award for a three-year program from the U.S. Department of Defense (DoD).
The award will be used to partially fund a Phase
1b/2, placebo-controlled, dose escalation clinical study of Armata’s
therapeutic phage-based candidate, AP-SA02, for the treatment of
complicated Staphylococcus aureus bacteremia infections, a bacterial
infection of the bloodstream.
The primary objectives of the study will be to
evaluate the safety and tolerability of AP-SA02 as an adjunct to best
available antibiotic therapy, and to determine the appropriate dose or
doses for future clinical trials of efficacy.
Armata does not expect the clinical trial to initiate prior to mid-2021.
https://seekingalpha.com/news/3583725-armata-pharma-nabs-15m-dod-award-to-treat-s-aureus-bacteremia-infections
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.